NeoGenomics Q3 revenue up 12% YoY to $188mln, reaffirms FY23 guidance.

• NeoGenomics reports 12% YoY increase in total revenue to $188 million in Q3 2025. • Clinical revenue grows 18% YoY, while NGS revenue increases 24% YoY. • NGS now accounts for nearly one-third of clinical revenue. • Net loss rises 53% to $27 million. • Adjusted EBITDA remains positive at $12 million.